Rockwell Medical, Inc. (NASDAQ:RMTI) stock is up during Wednesday’s premarket session, trading higher by 6.40% as the company has renewed a product purchase agreement with aQua Dialysis.
This agreement, which spans two years with options for two additional one-year extensions, underscores the company’s commitment to providing essential hemodialysis products.
The renewed agreement with aQua Dialysis allows Rockwell Medical to continue supplying liquid and dry hemodialysis concentrates, reinforcing its long-standing relationship with the provider.
“We are pleased to continue supporting aQua Dialysis through our renewed agreement that reflects the strength of our long-standing relationship,” said Chief Commercial Officer Tim Chole at Rockwell Medical.
This partnership is seen as a testament to Rockwell’s product quality and service reliability.
Technical Analysis
RMTI is sitting …
This post was originally published here
